Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Zhou S, Khanal S, Zhang H

Therapeutics and Clinical Risk Management 2019, 15:211-221

Published Date: 31 January 2019